STAGE III RENAL CELL CANCER AJCC V8

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare inherited form (HLRCC) or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood supply, …

This early-phase study tests whether adding a live bacteria product (EXL01) to standard immunotherapy (nivolumab + ipilimumab) is safe and helps control metastatic kidney cancer. About 33 adults with advanced renal cell carcinoma will receive either the standard drugs alone or wi…

This study tests whether adding inulin gel, a common fiber supplement, to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer. About 55 adults with cancer that has spread or is locally advanced will receive the combination. The goal is …

This study looks at whether getting immunotherapy in the morning or afternoon makes it more effective for people with advanced or metastatic solid tumors. Researchers think the body's internal clock might influence how the immune system responds. About 160 adults with certain can…

This study compares receiving the cancer drug nivolumab at home versus in a clinic for adults with several types of cancer. The goal is to see if home treatment reduces travel, cost, and stress while maintaining safety and effectiveness. About 50 participants will try both settin…

This study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 partici…